Chemotherapy Resistance in Osteogenic Sarcoma and Other Solid Tumors

NAActive, not recruitingINTERVENTIONAL
Enrollment

763

Participants

Timeline

Start Date

August 31, 1997

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2026

Conditions
Osteosarcoma
Interventions
OTHER

Tissue Procurement

MTX polyglutamylation, MTX transport, XTT cytotoxicity assays, Quantitative RT-PCR, Southern blotting, Mutation detection, and Western blotting

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

All Listed Sponsors
collaborator

Hospital for Special Surgery, New York

OTHER

collaborator

Weill Medical College of Cornell University

OTHER

collaborator

Columbia University

OTHER

collaborator

Rockefeller University

OTHER

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00580385 - Chemotherapy Resistance in Osteogenic Sarcoma and Other Solid Tumors | Biotech Hunter | Biotech Hunter